Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "EY"

3969 News Found

Eyestem moves closer to blindness breakthrough with phase 2 trial green light
R&D | January 29, 2026

Eyestem moves closer to blindness breakthrough with phase 2 trial green light

The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity


Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health
News | January 24, 2026

Amway India launches ‘Beyond Biotin’ Nutrilite Biotin C Plus to support skin, hair, nail health

The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc


Akums bags key EU GMP certifications for 2 Haridwar plants
News | January 24, 2026

Akums bags key EU GMP certifications for 2 Haridwar plants

Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms


Neurizon locks in global trademark protection across key pharma markets
News | January 21, 2026

Neurizon locks in global trademark protection across key pharma markets

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions


Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
R&D | January 21, 2026

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection


Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs
R&D | January 21, 2026

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments


EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
News | January 17, 2026

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike


Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
Clinical Trials | January 11, 2026

Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC

KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer


Newron secures key European patent for schizophrenia drug Evenamide
Biopharma | January 09, 2026

Newron secures key European patent for schizophrenia drug Evenamide

This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately